OCGNHealthcare · BiotechnologyThe 6 Wall Street analysts covering Ocugen, Inc. hold a median 12-month price target of $10 — +700.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Ocugen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Ocugen, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on OCGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +700.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 May 2026 | Canaccord Genuity | Maintains | Buy | $12 → $11 |
| 25 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Mar 2026 | Canaccord Genuity | Initiates | Buy | — |
| 11 Mar 2026 | Oppenheimer | Initiates | Outperform | — |
| 5 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Sept 2025 | Chardan Capital | Maintains | Buy | — |
| 4 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2025 | Chardan Capital | Maintains | Buy | — |
| 12 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Nov 2024 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 4% of US stocks
Cheaper than 2% of US stocks
Cheaper than 81% of US stocks
Higher than 38% of US stocks
Higher than 41% of US stocks
Higher than 5% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OCGN appears on the weeks it earns a place.
Ocugen, Inc. announced it will present on its modifier gene therapy platform at upcoming investor conferences in August 2026.
Why it matters — An OCGN watcher would care because the company is gaining visibility among investors by showcasing its gene therapy platform at industry conferences.
Ocugen announced that the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational product OCU410 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Why it matters — RMAT designation from the FDA can expedite the development and regulatory review of OCU410, a key pipeline asset for Ocugen.
Ocugen, Inc. announced it will host a conference call and webcast on August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide business updates.
Why it matters — The call will provide OCGN watchers with the company's latest financial performance and operational updates, which are key indicators of its progress in gene therapy development.
The 6 Wall Street analysts covering Ocugen, Inc. have a median 12-month price target of $10, with estimates ranging from $7 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Ocugen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocugen, Inc. 28 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Ocugen, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +700.0% from the last close, and Ticker Nerd's factor model ranks Ocugen, Inc. 28 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Ocugen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $22 over the next 12 months.
Ocugen, Inc. returned +25.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Ocugen Inc. is a biopharmaceutical company headquartered in Malvern, Pennsylvania, specializing in the discovery, development, and commercialization of gene therapies, cell therapies, and vaccines.
The most recent item we track (GlobeNewsWire, 31 July 2026): "Ocugen to Participate in Upcoming August Investor Conferences". Ocugen, Inc. announced it will present on its modifier gene therapy platform at upcoming investor conferences in August 2026.
Ocugen Inc. is a biopharmaceutical company headquartered in Malvern, Pennsylvania, specializing in the discovery, development, and commercialization of gene therapies, cell therapies, and vaccines. The company's primary focus centers on rare inherited retinal diseases, with its breakthrough modifier gene therapy platform designed to treat conditions like retinitis pigmentosa, leber congenital amaurosis, and Stargardt disease through products including OCU400, OCU410, and OCU410ST. Ocugen also develops OCU200, a fusion protein targeting diabetic macular edema and age-related macular degeneration. Beyond ophthalmology, the company pursues vaccine development with candidates including OCU500 for COVID-19, OCU510 for seasonal flu, and OCU520 combining both vaccine approaches. Additionally, Ocugen is advancing NeoCart, an autologous cell therapy for knee cartilage repair. The company collaborates with major research institutions including the National Institute of Allergy and Infectious Diseases and maintains a strategic partnership with CanSino Biologics for manufacturing its modifier gene therapy pipeline candidates. Ocugen operates as a fully integrated, patient-centric biotech enterprise committed to addressing significant unmet medical needs across ophthalmology, infectious disease, and orthopedics.
CEO Dr. Shankar Musunuri M.B.A., Ph.D. · 116 employees · United States · https://www.ocugen.com